CD19 and acute lymphoblastic leukemia: Clinical studies using CAR T cell targeting the canonical B cell marker, CD19, have demonstrated complete remission rates of 70-90% in B-ALL, driving FDA approval for patients <26 years with refractory B-ALL or disease in ≥2nd relapse (1–5).